ClinicalTrials.gg
CompletedNCT05475210Updated Oct 26, 2026

177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors

A Phase 1 interventional study of 177Lu-DOTA-EB-TATE and Amino Acid Solution in Neuroendocrine Tumors, sponsored by Molecular Targeting Technologies, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Molecular Targeting Technologies, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Oct 2025, 1 year ago, and no results have been posted to the registry.
Updated Oct 26, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 219 studies in Neuroendocrine Tumors with a site in United States — 45 open to participants now, 77 under way, 10 of them phase 3. Neuroendocrine Tumors · United States.

Enrollment
169th of 190
6 · median 35
Started
2022
with 11 others
Phase 1
47 of 219
9 open now
Registered
179th of 219
by date

Among the 219 studies in Neuroendocrine Tumors with a site in United States, this one is the 169th largest by enrollment of the 190 interventional ones that give a count, is one of 12 that started in 2022, is one of 47 in phase 1, and was the 179th registered.

Neuroendocrine Tumors

544 studies on the registry are indexed under Neuroendocrine Tumors; 136 are open to participants now.

Browse Neuroendocrine Tumors studies →

Open to participants now

45 of the 219 studies in Neuroendocrine Tumors with a site in United States are open now. Recruiting first, the newest first:

40 more — sign in →

All 45 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 111 Neuroendocrine Tumors studies recruiting now, 72 (65%) set no upper age limit and 17 (15%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 219 studies in Neuroendocrine Tumors with a site in United States, or all of them as a file.
02

Study summary

This is a Phase I clinical trial to assess the safety and dosimetry profiles of 177Lu-DOTA-EB-TATE in patients with advanced, metastatic or inoperable, somatostatin receptor-positive, well-differentiated GEP-NETs.

03

Conditions studied

  • Neuroendocrine Tumors

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Ability to understand and willing to sign a written document

Aged 18 years or older

proven or cytologically confirmed, inoperable, GEP-NETs

Neuroendocrine tumors (NETs) of grade 1, 2 and 3 according to World Health Organization (WHO) 2017 classification

as defined by Response Criteria in Solid Tumors () version 1.1

Overexpression of somatostatin receptors of the target lesions in 68Ga-DOTA-TATE positron emission tomography (PET)/computed tomography (CT) with SUV of lesions greater than normal liver in at least 1 lesion

A calculated creatinine clearance > 60 mL/min

performance status scale ≥ 70%

Women of and men must agree to use adequate prior to study entry and for the duration of study participation, including follow-up (7 months after the last dose of study drug for women and 4 months for men).

Previous local therapy (e.g., chemoembolization or bland embolization) is allowed if completed >4 weeks prior to study entry.

Previous surgery no less than 6 weeks prior to study entry.

Either no prior treatment with 177Lu-DOTA-TATE or at least 12 months progression-free survival (PFS) after prior treatment with 177Lu-DOTA-TATE

Exclusion criteria

Exclusion Criteria:

Women who are pregnant or breastfeeding

History of allergic reactions attributed to compounds of similar chemical or biologic composition to 177Lu-DOTA-EB-TATE as assessed from medical records

Previous treatment with more than 4 cycles of 177Lu-DOTA-TATE

Participant has had prior chemotherapy, targeted cancer therapy, immunotherapy, or treatment with an anticancer agent within 4 weeks or 4 half-lives whichever is longer, before the first administration of study drug.

Participant has not fully recovered from major surgery or significant traumatic injury prior the first dose of study drug or expects to have major surgery during the study period or within 3 months after the last dose of study drug.

\< 6 months as assessed by the treating physician

> 80% liver involvement by tumor

> 25% bone marrow involvement by tumor

Poorly differentiated neuroendocrine neoplasms, such as poorly differentiated neuroendocrine carcinoma, small- and large-cell neuroendocrine carcinoma; mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN); Grade 3 neuroendocrine carcinomas (NEC)

Presence of somatostatin receptor negative lesions if they cannot be addressed with loco-regional therapies prior to the treatment start

Deteriorated renal function, as indicated by a serum > 1.7 mg/dL

Deteriorated bone marrow function

Deteriorated liver function

Toxicities from prior therapies that have not resolved to grade 1 or grade 0

Active and bacterial, fungal, or viral infection, including (HBV), (HBC), know (HIV), or acquired immunodeficiency syndrome (AIDS)-related illness

Known and/or carcinomatous meningitis, unless these have been treated and stabilized

Uncontrolled diabetes mellitus as defined by a >9%

Impossibility to interrupt short-acting octreotide for 24 h before and 24 h after the administration of 177Lu-DOTA-EB-TATE; impossibility to have an interval of ≥4 weeks between octreotide and 177Lu-DOTA-EB-TATE

The use of somatostatin and its analogues within 4 months of a planned 177Lu-DOTA-EB-TATE treatment

Uncontrolled, intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

Prior external beam radiation therapy involving >25% of the bone marrow

Unmanageable urinary incontinence rendering the administration of 177Lu-DOTA-EB-TATE unsafe

Other known co-existing except non-melanoma skin cancer and carcinoma in situ of the uterine cervix, unless definitively treated and with no evidence of recurrence

Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Peptide Receptor Radionucleotide Therapy (PRRT)

    The treatment regimen will consist of a single-dose intravenous administration of 177Lu-DOTA-EB-TATE per 6-week cycle, for a total of 2 cycles. The dose per cycle will be fixed for each patient and will be escalated in 3 different dose levels, from 50 mCi to 150 mCi (1.85 -5.55 GBq). Each dose of 177Lu-DOTA-EB-TATE will be administered in association with intravenous renal protective amino acid solutions.

    Drug: 177Lu-DOTA-EB-TATE · Other: Amino Acid Solution

Interventions

  • DrugLutetium Lu 177-DOTA-EB-TATEStudies of Lutetium Lu 177-DOTA-EB-TATELutetium Lu 177-DOTA-EB-TATE pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Peptide Receptor Radionucleotide Therapy ( PRRT) using 177Lu-DOTA-EB-TATE with a defined number of cycles will be administered.

  • OtherAmino Acid Solution

    The Amino acid solution to be used in this study will contain a mixture of lysine and arginine diluted in an electrolyte solution.

    Also known as: Arginine-Lysine Solution

06

What researchers measure

Primary outcomes

  1. To evaluate the safety of 177Lu-DOTA-EB-TATE assessed from the number of patients with treatment-related adverse events.

    Time frame: 16-17 months

  2. To identify the dose-limiting toxicities (DLTs) of escalating doses of 177Lu-DOTA-EB-TATE up to 150 mCi.

    Time frame: 16-17 months

  3. To determine if the maximum tolerated dose is among the explored doses of 50, 100 and 150 mCi.

    Time frame: 16-17 months

Secondary outcomes

  1. To evaluate the differential safety of 177Lu-DOTA-EB-TATE, expressed as the number of patients with treatment-related adverse events following 177Lu-DOTA-EB-TATE.

    Time frame: 16-17 months

  2. To evaluate dosimetry levels in patients following 2 cycles of 177Lu-DOTA-EB-TATE.

    Time frame: 16-17 months

07

Study locations

1 site
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Oct 2025, 40 months.

Of 54 phase 1 interventional studies under Neuroendocrine Tumors, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 75. This study's 40 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Dec 2024 → Oct 2025 and completion Mar 2025 → Dec 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2022
First posted
Jul 26, 2022
StartActual
Jun 18, 2022
Primary completionActual
Oct 29, 2025was Dec 2024
CompletionActual
Dec 31, 2025was Mar 2025
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 26, 2026
Primary completion
Dec 31, 2024→Oct 29, 2025 (actual)
Oct 26, 2026
Study completion
Mar 30, 2025→Dec 31, 2025 (actual)
Oct 26, 2026
Enrollment
9 (estimated)→6 (actual)
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Recruiting→Completed
    Primary completion Dec 31, 2024→Oct 29, 2025 (now actual)
    Study completion Mar 30, 2025→Dec 31, 2025 (now actual)
    Enrollment 9 (estimated)→6 (actual)
    + 4 other changes: verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05475210
Lead sponsor
Molecular Targeting Technologies, Inc.
Collaborators
ClinSmart
Responsible party
Sponsor
First posted
Jul 26, 2022
Start date
Jun 18, 2022
Primary completion
Oct 29, 2025
Completion
Dec 31, 2025
Last update
Oct 26, 2026

Study contacts

Lisa Bodei, MD, PhD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lutetium Lu 177-DOTA-EB-TATE

Start the discussion